This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
and you are
over 18
years old
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

A phase 1 dose-escalation trial to assess the safety, tolerability, and pharmacodynamics of PF-04691502 in adult cancer patients with solid tumors.

Provided treatments

  • Drug: PF-04691502
Tris trial is registered with FDA with number: NCT00927823. The sponsor of the trial is Pfizer and it is looking for 37 volunteers for the current phase.
Official trial title:
A Phase 1, Open-Label, Dose-Escalation Study To Evaluate Safety, Pharmacokinetics, And Pharmacodynamics Of The PI3K/MTOR Inhibitor PF-04691502 In Adult Patients With Advanced Malignant Solid Tumors